<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; Effient</title>
	<atom:link href="http://www.rxtimes.com/tag/effient/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy</title>
		<link>http://www.rxtimes.com/new-analysis-assesses-impact-of-common-genetic-variation-on-benefit-of-antiplatelet-therapy/</link>
		<comments>http://www.rxtimes.com/new-analysis-assesses-impact-of-common-genetic-variation-on-benefit-of-antiplatelet-therapy/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 13:40:23 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Acute Coronary Syndromes]]></category>
		<category><![CDATA[Antiplatelet Therapy]]></category>
		<category><![CDATA[Daiichi Sankyo]]></category>
		<category><![CDATA[Effient]]></category>
		<category><![CDATA[Lilly]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=4638</guid>
		<description><![CDATA[PARSIPPANY, N.J. and INDIANAPOLIS, March 15, 2010 - A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix(R) (clopidogrel) plus aspirin or Effient(R) (prasugrel) plus aspirin and managed [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/new-analysis-assesses-impact-of-common-genetic-variation-on-benefit-of-antiplatelet-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

